INTRODUCTION
Colorectal cancer is globally considered as the most common cancer found in people of all age groups and alone constitutes 10 % of cancerrelated deaths [1] . It is a malignant neoplasm originating from the lining of the colon. Colorectal cancer metastasizes to various distant organs and its most common target is the liver. One type of colon cancer is colitis-associated cancer which is characterized by the onset of inflammatory bowel disease of ulcerative colitis [2] . It has been reported that 15 % of patients with colorectal cancer show liver metastases [3] . Among various types of solid tumors only in patients with colorectal cancer can the survival term be increased by surgical extraction of distant metastases from various organs such as liver and lungs [4] . The survival of the unresectable metastases of colorectal cancer patients can be increased by treatment with systemic chemotherapy [5] .
Cell apoptosis is a programmed mechanism for death of unwanted cells which can take place via intrinsic or extrinsic pathways [6, 7] . Various ligands interact with surface receptors (tumor necrosis factor) and death receptors leading to cell apoptosis through extrinsic pathway [7, 8] . However, cellular processes like oxidative stress, DNA damage and cytotoxic agents lead to apoptosis through the intrinsic pathway [7] .
In caspase dependent method of apoptosis various proteins such as components of Bcl-2 class are involved in the maintenance of activation of caspases [9, 10] .Treatment of cancer by induction of cell apoptosis using chemotherapeutic agents is one of the best strategies. Therefore, screening of new molecules for the development of treatment strategy can improve the clinical outcome for patients with colorectal cancer.
Capecitabine is a modified derivative of fluoropyrimidine aimed to selectively transfer 5-fluorouracil into tumor cell. The method of administration of capecitabine is very simple and comfortable. In gastric cancer treatment capecitabine is used either singly or in combination with other chemotherapeutic agents [11] . Administration of higher doses of capecitabine to patients of gastric cancer cause side effects such as diarrhea, lymphopenia, nausea etc. However, lower doses have been found to be effective.
In the present study effect of capecitabine on viability and apoptosis induction in human colon cancer cells was investigated. The study demonstrated that capecitabine treatment at lower doses causes inhibition of colon cancer growth via mitochondrial pathway of apoptosis. Thus capecitabine can be a very good candidate for the treatment of colon cancer.
EXPERIMENTAL Chemicals and reagents
Capecitabine was purchased from Roche Pharmaceutical Company (Nutley, NJ, USA) and its solution was freshly prepared at the time of use in dimethylsulfoxide (DMSO). Propidium iodide, Triton X-100, Tris-HCl and trypan blue were supplied by Sigma Chemical Co (St Louis, MO, USA).
Cell culture and cell viability assay
HCT-15 human colon cancer cell line purchased from Food Industry Research and Development Institute (Hsinchu, Taiwan). The cell cultureswere grown in RPMI-1640 (Gibco BRL) containing 10 % fetal bovine serum (FBS, HyClone). The medium was supplemented with 2 mM glutamine (Sigma-Aldrich) and antibiotics such as penicillin (100 U/mL) and streptomycin (100 µg/mL). The cells were cultured in an incubator at 37 o C temperature under 5 % CO 2 atmosphere.
Determination of cell morphology and viability
HCT-15 cells at 4 x 10 4 cells per well density were distributed in 12-well plates and incubated for 24 h. The cells were then subjected to 48 h incubation with 0, 1, 2, 3, 4 and 5 μM doses of capecitabine under an atmosphere of 5 % CO 2 at 37 ˚C.
After incubation phase-contrast microscope was used to examine the cells for changes in morphology. For analysis of viability the cells were collected after incubation with capecitabine, centrifuged and then subjected to PI (5 μg/mL) staining before analysis using flow cytometry (Becton-Dickinson, San Jose, CA, USA).
Analysis of apoptosis
HCT-15 cells after incubation with or without capecitabine for 48 h were collected and trypsinized. The cells were then washed twice with phosphate-buffered saline and subsequently resuspended at a density of 2 x 10 6 cells per ml in binding buffer.
The cells were then treated with 5 µL each of annexin-V-fluorescein isothiocyanate and propidium iodide (PI) and subjected to incubation for 15 min at room temperature. FACScalibur Flow Cytometer (BD Biosciences, San Jose, CA, USA) was used for the analysis of cell apoptosis.
Analysis of cell cycle
HCT-15 cells after incubation with or without capecitabine for 48 h were collected and trypsinized. The cells were collected and then fixed overnight at 4 o C using 70 % ethyl alcohol. The cells were re-suspended in the dark at 37 o C for half an hour in PBS supplemented with PI (40 μg/mL) and RNase (0.1 mg/mL) Triton X-100 (0.1 %). Flow cytometer connected with an argon ion laser was used for analysis of the cells at a wavelength of 490 nm.
Determination of reactive oxygen species (ROS) production
HCT-15 cells at density of 2 x 10 6 cells per mL were incubated with indicated doses of capecitabine for 48 h. The cells were collected and treated with 10 μM solution of 2, 7-dichlorodihydrofluorescein diacetate (DCFH-DA) for half an hour at 37 ˚C. After incubation the cells were analyzed using flow cytometry for production of reactive oxygen species.
Western blot analysis
HCT-15 cells after incubation with capecitabine for 48 h under the appropriate conditions were collected and washed two times with ice-cold PBS. The cells were then treated with lysis buffer [40 mM Tris (pH 8.0), sodium chloride (120 mM), NP-40 (0.5 %), sodium or thovanadate (0.1 mM), aprotinin (2 µg/mL), leupeptin (2 µg/mL) and phenymethylsulfonyl fluoride (100 µg/mL)] to get the lysate. From the lysate supernatant was collected to determine the concentration of proteins (Pierce, Rockford, IL). The non-specific sites in the membranes were blocked for 1 h with 5 % non-fat dry milk in Trisbuffered saline with Tween-20 buffer at room temperature. Membrane incubation with primary antibodies was performed overnight. Following incubation 4 X TBS-T buffer was used for washing of the membrane for 15 min followed by 1 h incubation with horseradish peroxidaseconjugated anti-rabbit or anti-mouse immunoglobin (Santa Cruz Biotechnology Inc., Santa Cruz, CA).
Thereafter, 1 X TBS-T buffer was used for washing the membrane for 15 min. The complex format on interaction of antigen with antibody was analyzed using enhanced chemiluminescence (ECL) detection system (GE Healthcare Biosciences, Pittsburgh, PA). The primary antibodies against caspase-9, -3, -8, Bax, Bal-2, Endo G, AIF and PARP were obtained from R&D Systems (Minneapolis, USA) whereas those against Cdc25c, cyclin E, pp53and p21were obtained from Santa Cruz Biotechnology (CA).
Confocal laser scanning microscopy for protein translocation
HCT-15cells were distributed at a density of 2 x 10 5 cells per well onto 4-well chamber slides and cultured. The cells were incubated without or with the indicated concentration of capecitabine for 48 h. Cells on the slides were fixed for over 20 min using 4 % formaldehyde in PBS. The cells were permeabilized by treatment with Triton-X 100 (0.3 %) in PBS for 1 h. The non-specific sites blocked with 2 % BSA. Staining of the cells was performed overnight by incubation with primary antibodies against AIF and Endo G (1 : 100 dilution). The stained cells were incubated with secondary antibody (FITC conjugated goat antimouse IgG at 1 : 100 dilution) and subsequently subjected to DNA staining using mitotracker. Leica TCS SP2 confocal spectral microscope was used for obtaining the photomicrographs.
DAPI staining
HCT-15cellsat a density of 2 X 10 5 cells per ml were incubated with or without capecitabine for 48 h. After incubation the cells were subjected to DAPI (4, 6-diamidino-2-phenylindole dihydrochloride) staining. Then fluorescence microscope was used for examination of the stained cells.
Statistical analysis
The data are expressed as mean ± standard deviation (SD). Student's t-test was used for the analysis of the differences among the groups; p < 0.05 was considered statistically significant.
Microsoft Excel 2007 was used for the analysis

RESULTS
Capecitabine alters the morphology and reduces viability of HCT-15 cells
Phase-contrast microscopy showed changes in the morphological appearance of HCT-15 cells on incubation with capecitabine. Changes in the cell morphology were dependent on the concentration of capecitabine. Flow cytometry revealed that capecitabine treatment significantly (p < 0.005) reduced the viability of HCT-15 cells. At 5 μM concentration of capecitabine the viability of HCT-15 cells was reduced to 23 % compared to 98 % in the control cultures ( Figure  1B ). 
Capecitabine treatment of HCT-15 cells causes induction of apoptosis
The results from DAPI and Annexin V staining revealed that capecitabine treatment of HCT-15 cells caused condensation of DNA and induced apoptosis in concentration dependent manner (Figure 3) . At 5 μM concentration of capecitabine apoptosis was induced in 45.74 % of HCT-15 cells after 48 h compared to 3.39 % in the control.
Capecitabine increases reactive oxygen species production (ROS) in HCT-15 cells
Incubation of HCT-15 cells with various concentrations of capecitabine for 48 h led to increase in the production of ROS in concentration dependent manner. The production of ROS was significantly higher at 5 μM concentration of capecitabine after 48 h (Figure 4 ). 
Capecitabine increases translocation of Endo
DISCUSSION
The current study was aimed to investigate the effect of various concentrations of capecitabine on HCT-15 human colon cancer cells. The results showed a decrease in viability and increase in apoptosis of HCT-15 cells via mitochondrial pathway on exposure to capecitabine. Incubation of HCT-15 cells with capecitabine led to reduction in viability to a marked level based on the concentration used. Progression of cell cycle through various phases is regulated by different kinases which play important role in the action of cdc/cdk kinases [12] . Cyclins D/cdk on activation regulate progression of G1, E/cdk2 activation G1/S, A/cdk2 activation S and cyclin A and cyclin B/cdk1 regulate progression of G2/M phases [13, 14] . Investigation of the underlying mechanism of capecitabine induced reduction in HCT-15 cell viability revealed arrest of cell cycle in G0/G1 phase. TheG0/G1 phase arrest was further confirmed by increase in p53 and p21 expression and decrease in Cdc25c and cyclin E level in capecitabine treated cells. Up-regulation of Bax expression causes increase in the mitochondrial membrane permeability which results in activation of caspases and subsequently cell apoptosis [15] [16] [17] . In HCT-15 cells incubation with capecitabine induced apoptosis significantly and increased the activation of caspases.
The mitochondrial translocation of proteins AIF and Endo G was increased significantly on incubation of HCT-15 cells with capecitabine. The level of pro-apoptotic protein (Bax) expression was promoted in the cells incubated with capecitabine. On the other hand, the antiapoptotic protein Bcl-2 expression was decreased. It is reported that increase in the generation of cellular reactive oxygen species induces cell cycle arrest and apoptosis [18, 19] . Results from the current study showed that incubation of HCT-15 cells with capecitabine led to increase in the production of reactive oxygen species. There are reports that increase in the expression level of p21 in the cells is related with the JNK pathway activation [20] . The results from the present study showed that capecitabine treatment of HCT-15 cells significantly increased the expression of p21.
CONCLUSION
Capecitabine treatment causes inhibition of colon cancer growth via the mitochondrial pathway of apotposis. Thus, capecitabine may be useful for the treatment of colon cancer.
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